Proteostasis Therapeutics Inc (NASDAQ:PTI) Director Franklin M. Berger acquired 40,000 shares of the stock in a transaction dated Friday, October 26th. The stock was acquired at an average cost of $6.75 per share, with a total value of $270,000.00. Following the transaction, the director now owns 266,162 shares of the company’s stock, valued at $1,796,593.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
PTI stock traded up $0.64 during trading on Friday, reaching $5.99. 5,943,194 shares of the stock traded hands, compared to its average volume of 1,629,514. Proteostasis Therapeutics Inc has a 52-week low of $1.41 and a 52-week high of $10.38. The company has a market cap of $264.22 million, a PE ratio of -2.56 and a beta of 3.93.
Proteostasis Therapeutics (NASDAQ:PTI) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($0.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.04). The company had revenue of $0.84 million for the quarter, compared to analyst estimates of $1.16 million. Proteostasis Therapeutics had a negative return on equity of 96.44% and a negative net margin of 1,086.77%. Equities analysts predict that Proteostasis Therapeutics Inc will post -2.01 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the business. Schwab Charles Investment Management Inc. lifted its stake in shares of Proteostasis Therapeutics by 156.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 46,900 shares of the company’s stock worth $131,000 after purchasing an additional 28,600 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Proteostasis Therapeutics during the second quarter worth about $141,000. Element Capital Management LLC acquired a new position in shares of Proteostasis Therapeutics during the first quarter worth about $158,000. Bank of New York Mellon Corp lifted its stake in shares of Proteostasis Therapeutics by 252.8% during the second quarter. Bank of New York Mellon Corp now owns 62,319 shares of the company’s stock worth $174,000 after purchasing an additional 44,653 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Proteostasis Therapeutics by 82.2% during the first quarter. Northern Trust Corp now owns 43,034 shares of the company’s stock worth $204,000 after purchasing an additional 19,416 shares in the last quarter. Institutional investors own 64.58% of the company’s stock.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study.
Featured Article: Using the New Google Finance Tool
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.